Patient-Reported Outcomes in Cancer Supportive Care
Symposium
Symposium

Patient-Reported Outcomes in Cancer Supportive Care

Letting the Patient Be Your Guide: Using Patient-Reported Outcomes to Provide Optimal Supportive Care in Oncology

Not a member of My prIME? Join now for instant access.

Meeting Overview

Expand your arsenal of patient-reported outcomes tools and find out how they can impact your practice. This satellite symposium at the European Oncology Congress in Madrid includes for an in-depth exploration of supportive care in oncology focused on how to provide the best possible care for patients by incorporating patient-reported outcomes into your standard of care.

Date and Location

Sunday, 10 September 2017
18.30 – 20.00 

Cordoba Auditorium, Hall 4
IFEMA – Feria de Madrid
Madrid, Spain

Date/Time

Date/Time

Sunday, 10 September 2017
18.30 – 20.00

Location

Location

Madrid, Spain

CME

CME

1.5 AMA PRA Category 1 Credits

18.30 Welcome and introduction
Florian Strasser, MD
18.35 Assessing what you know about supportive care
Florian Strasser, MD
18.40 Overview on the impact of treatment on patient well-being in oncology
Florian Strasser, MD
18.50 Focus on economics in supportive care: Comparing treatment costs to the cost of not treating
Alexander Molassiotis, RN, PhD
19.05 Overview on current and emerging tools for identifying and capturing patient-reported outcomes (PROs) in cancer care
Stein Kaasa, MD, PhD
19.15 These tools really work: Current data on the impact of using PROs in assessing patient symptoms/quality of life and potential barriers that may prevent their implementation
Stein Kaasa, MD, PhD
19.25 Committing to practice change
Stein Kaasa, MD, PhD
19.30 Current and emerging treatment options for commonly-reported symptoms/issues in oncology
Richard Gralla, MD, FACP
19.50 Assessing what you have learned
Florian Strasser, MD
19.55 prIME Points™
Florian Strasser, MD
20.00 Adjourn

    CHAIR

  • Florian Strasser, MDCantonal Hospital St Gallen
    St Gallen, Switzerland
  • FACULTY

  • Richard Gralla, MD, FACPAlbert Einstein College of Medicine
    New York, New York, United States
  • Stein Kaasa, MD, PhDOslo University Hospital and Oslo University
    Oslo, Norway
  • Alexander Molassiotis, RN, PhDThe Hong Kong Polytechnic University
    Hong Kong, China

This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, surgical oncologists, radiation oncologists, hematology/oncology nurses, and other healthcare professionals involved in providing supportive care to patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Assess the impact that cancer treatment can have on patient quality of life, general well-being, and overall functioning
  • Identify current and emerging tools that can aid in the assessment of PROs in oncology
  • Interpret data on the impact of using PROs on patient quality of life, general well-being, and overall functioning in the oncology setting
  • Develop optimal supportive care strategies for patients with cancer who experience issues such as chemotherapy-induced nausea and vomiting, chemotherapy-induced diarrhea, and cancer cachexia
  • Analyze efficacy and safety data on emerging treatment strategies in supportive care

This educational activity is supported by a grant from Helsinn Healthcare SA.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME

Provider

This activity is provided by prIME Oncology.

SUNSHINE ACT AND EFPIA DISCLOSURE CODE

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.